Safety Reference
Danger
H360May damage fertility or the unborn child
H361Suspected of damaging fertility or the unborn child
H371May cause damage to organs
H373
Sourcing Relugolix?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxy-3-pyridazinyl)-6-(4-nitrophenyl)-
pharmaceutical intermediate
Sourcing Relugolix?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used as a pharmaceutical raw material. It is notable as the first orally administered GnRH receptor antagonist approved for advanced prostate cancer, offering a less burdensome option compared to injectable therapies.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
The international HS code for Relugolix (CAS 737789-87-6) is 2934.99.
2934.99
2934 99 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
AOMXMOCNKJTRQP-UHFFFAOYSA-N
CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC